Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

E-ISSN： 1399-0012|29|7|654-663

ISSN： 0902-0063

Source： CLINICAL TRANSPLANTATION (ELECTRONIC), Vol.29, Iss.7, 2015-07, pp. : 654-663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 603-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1748-1755

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

Oncology, Vol. 84, Iss. 1, 2012-10 ,pp. : 43-56

Karger

Access to resources Recommend Favorite

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 368-376

John Wiley & Sons Inc

Access to resources Recommend Favorite

Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor‐specific antibodies

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 27, Iss. 8, 2014-08 ,pp. : 775-783

John Wiley & Sons Inc

Access to resources Recommend Favorite